Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
42 participants
INTERVENTIONAL
2009-07-31
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Preliminary data also indicate that modulation of serotonin function by antidepressant treatment in healthy volunteers with high neuroticism traits could modify the brain activity associated with the processing of emotional stimuli that is dysfunctional in this vulnerable population.
The aim of this research is to investigate further whether modulation of serotonin function via administration of serotonergic antidepressants (SSRIs) can revert the dysfunctional emotion processing that characterises subjects with the personality trait of high neuroticism.
In particular we hypothesise that SSRI administration will modify the abnormal patterns in attention, physiological reactivity and regulation of emotional stimuli present in healthy individuals with the vulnerable personality trait of high neuroticism.
Carrying out this research on healthy volunteers will enable us to understand if modulating serotonin function by antidepressant administration has an effect not only on mood symptoms - as is evident in depressed patients - but also on the predisposing psychological and cognitive processes that sustain the depressed mood, such as the response to emotional stimuli. We will also be able to verify if this effect is shown early treatment and prior to any subjective changes in mood. This will be done by administering seven days of either the antidepressant citalopram or placebo to subjects with high neuroticism scores and then comparing them on a series of computer based psychological tests measuring various aspects of how emotionally salient stimuli are processed.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be requested to come to the Department of Psychiatry of the University of Oxford for an initial screening assessment including basic medical examination and structured psychiatric interview. On that occasion they will also be asked to complete a number of questionnaires such as Beck Depression Inventory, Dysfunctional Attitudes Scale, State-Trait Anxiety Inventory, Eysenck Personality Questionnaire, Parental Bonding Instruments and Life Events Rating Scale.
Volunteers will be randomized to receive citalopram or placebo in a double blind between groups design for 7 days. They will receive the treatment capsules to take home and will be instructed to take the capsule every morning after breakfast around 8 am. Subjective mood will be assessed on each day of treatment using the Befindlichskeit scale of mood and energy, the State Anxiety Inventory and Visual Analogue Scales. Side-effects will be registered every day using a specific side-effects report sheet.
On the day before starting the treatment (Day 0) and on the last day of treatment (Day 7) participants will be asked to collect saliva sample to measure cortisol levels. Collection of samples will be performed by participants in their own home and is non-invasive. Participants will be provided with appropriate collection vessels containing a cotton swab. They will be asked to roll this swab around in their mouths for a minute after waking and take 4 further samples at 15 minute intervals, each on a separate cotton swab. The cotton swabs will be put back in the collection vessel and participants will be asked to store their saliva samples in the freezer and bring them back to the researcher on the day of testing.
Participants will be given the mobile phone number of the Principal Investigator (PI) so that they can immediately get in contact if they have any concerns when taking the drug. In addition, the researcher will contact participants within the first few days to ensure that they are not experiencing any side effects. Participants experiencing more than mild transient side effects will be advised to stop taking the drugs and will be withdrawn from the study.
On the last day of treatment (Day 7), participants will come to the Department of Experimental Psychology of the University of Oxford around 2 pm, which corresponds to time when the drug reaches its peak in blood levels. They will be asked to complete again part of the questionnaires administered on the first day and then they will complete a battery of neuropsychological tests including attentional tests, facial expression recognition tests and emotional regulation tests, as used in our previous studies. During the emotional regulation test an ECG will also be recorded. The testing session will last approximately 3 hours.
If the participant agreed, we would then also collect a blood sample to identify a particular gene (the serotonin transporter polymorphism) that may influence some of those measures and to assess the citalopram drug level in order to check that the treatment was taken.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Citalopram
20 mg citalopram capsule, 1/ day, after breakfast (approximately 8am), for 7 days
Citalopram
Placebo
Placebo capsule 1/ day, after breakfast (approximately 8am), for 7 days
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Citalopram
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or Female, aged 18 - 50 years
* Eysenck Personality Questionnaire Neuroticism scale ≥15/24
* Fluent in English language (in order to understand all study instructions and tasks using verbal stimuli)
Exclusion Criteria
* current or past history of psychiatric disorder
* family history of mania
* pregnancy or breastfeeding
* taking any current medication (except the contraceptive pill)
* having taken part in other trials involving psychotropic drug intake in the previous three months
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Martina Di Simplicio
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martina Di Simplicio, MD
Role: PRINCIPAL_INVESTIGATOR
University of Oxford (at the time of study); MRC Cognition and Brain Sciences unit (current)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Oxford, Department of Psychiatry, Warneford Hospital
Oxford, Oxfordshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09/H0605/60
Identifier Type: -
Identifier Source: org_study_id